Esketamin zur Behandlung von Depression
Anmelder: Janssen Pharmaceutica NV 🇧🇪
Details
- Veröffentlichungs-Nr.
- EP4755453
- Anmeldetag
- 21. Dezember 2018
- Veröffentlichung
- 10. Juni 2026
- Rechtsraum
- EP
- IPC
- A61K31/135, A61P25/24A61P25/24
Abstract
The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
Anmelder
- Firma
- Janssen Pharmaceutica NV
- Land
- 🇧🇪 Belgien
Janssen Pharmaceutica ist ein belgisches Pharmaunternehmen mit Sitz in Beerse, das 1953 von Paul Janssen gegründet wurde und seit 1961 zum US-Konzern Johnson & Johnson gehört. Es entwickelt Arzneimittel unter anderem in den Bereichen Onkologie, Immunologie und Neurowissenschaften.
2.272 Patente in unserer Datenbank